FDA Issues Warning Letters on Marketing and Sale of OTC CBD Products


The U.S. Foods and Drug Administration (Fda)¬†issued warning letters¬†this month to two organizations regarding the advertising and marketing and sale of over-the-counter (OTC) drug products that contains cannabidiol (CBD) as an inactive component. The letters allege violations of the Federal Food items, Drug, and Cosmetic (FD&C) Act relevant to recent great producing exercise specifications and […]